Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

* No prior anthracycline use

* PS less or equal 2

* Lab values within certain limits (ANC greater 1000, platelets greater 100,000; ALT, AST 2 time ULN, creatinine less 2.0)

* No more than 3 prior chemotherapy regimens, only 2 of which can have included platinum-containing regimens

* Use of effective means of contraception in subjects of child-bearing potential

* Evidence of complete or partial bowel obstruction

* Need for IV hydration or TPN

* Greater 2 prior abdominal surgeries

* History of gastrointestinal perforation

* Gastrointestinal perforation due to any other cause within the last 6 months

* Inability to comply with study and/or follow-up procedures

* Life expectancy of less than 12 weeks

* Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin cancer study

* Inadequately controlled hypertension (defined as systolic blood pressure 150 and/or diastolic blood pressure greater 100 mmHg on antihypertensive medications)

* Any prior history of hypertensive crisis or hypertensive encephalopathy

* New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E)

* History of myocardial infarction or unstable angina within 6 months prior to study enrollment

* History of stroke or transient ischemic attack within 6 months prior to study enrollment

* Known CNS disease

* Significant vascular disease (e.g., aortic aneurysm, aortic dissection)

* Symptomatic peripheral vascular disease

* Evidence of bleeding diathesis or coagulopathy

* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study

* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment

* History of abdominal fistula, or intra-abdominal abscess within 6 months prior to study enrollment

* Serious, non-healing wound, ulcer, or bone fracture

* Proteinuria at screening as demonstrated by either:

* Urine protein:creatinine (UPC) ratio 1.0 at screening OR

* Urine dipstick for proteinuria greater or equal 2plus (patients discovered to have greater or equal 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate less or equal 1g of protein in 24 hours to be eligible)

* Known hypersensitivity to any component of Avastin

* Pregnant (positive pregnancy test) or lactating. No effective means of contraception (men and women) in subjects of child-bearing potential